CCNDBP1, cyclin D1 binding protein 1, 23582

N. diseases: 21; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0019207
Disease: Hepatoma, Morris
Hepatoma, Morris 		0.300 Therapeutic disease CTD_human Expression of GCIP in transgenic mice decreases susceptibility to chemical hepatocarcinogenesis. 16501603 2006
CUI: C0019208
Disease: Hepatoma, Novikoff
Hepatoma, Novikoff 		0.300 Therapeutic disease CTD_human Expression of GCIP in transgenic mice decreases susceptibility to chemical hepatocarcinogenesis. 16501603 2006
CUI: C0023904
Disease: Liver Neoplasms, Experimental
Liver Neoplasms, Experimental 		0.300 Therapeutic phenotype CTD_human Expression of GCIP in transgenic mice decreases susceptibility to chemical hepatocarcinogenesis. 16501603 2006
CUI: C0086404
Disease: Experimental Hepatoma
Experimental Hepatoma 		0.300 Therapeutic disease CTD_human Expression of GCIP in transgenic mice decreases susceptibility to chemical hepatocarcinogenesis. 16501603 2006
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.040 Biomarker group BEFREE miR-9 Modulates Osteosarcoma Cell Growth by Targeting the GCIP Tumor Suppressor. 26107195 2015
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.040 Biomarker group BEFREE Rad translocates GCIP from the nucleus to the cytoplasm, thereby inhibiting the tumor suppressor activity of GCIP, which occurs in the nucleus. 20460530 2010
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.040 AlteredExpression group BEFREE Overexpression of GCIP in SW480 colon cancer cell line resulted in a significant inhibition on tumor cell colony formation, while silencing of GCIP expression by siRNA can promote cell colony formation. 17131381 2007
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.040 Biomarker group BEFREE Although GCIP has little inhibition on the number of hepatic tumors at later stages (40 weeks), hepatocellular tumors in GCIP transgenic mice are smaller and well-differentiated compared to the poorly differentiated tumors in wild-type mice. 16501603 2006
CUI: C0043194
Disease: Wiskott-Aldrich Syndrome
Wiskott-Aldrich Syndrome 		0.010 Biomarker disease BEFREE We discover a key biochemical difference between Dip1 and WASP that may limit linear filament nucleation in cells; although WASP must be released for nucleation, Dip1 stays associated with Arp2/3 complex on the pointed ends of nucleated actin filaments, so Dip1 is consumed in the reaction. 31564494 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis 		0.010 Biomarker disease BEFREE Among them, the downregulation of the E3 ubiquitin ligase DIP1 was closely related to death-associated protein kinase stabilization along the normal mucosa-UC-UCC sequence. 26083618 2015
CUI: C0029463
Disease: Osteosarcoma
Osteosarcoma 		0.010 Biomarker disease BEFREE In sum, these results highlight the importance of miR-9 as an oncogene in regulating the proliferation of osteosarcoma by directly targeting GCIP and may provide new insights into the pathogenesis of osteosarcoma. 26107195 2015
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone 		0.010 Biomarker disease BEFREE In sum, these results highlight the importance of miR-9 as an oncogene in regulating the proliferation of osteosarcoma by directly targeting GCIP and may provide new insights into the pathogenesis of osteosarcoma. 26107195 2015
CUI: C1332986
Disease: Childhood Osteosarcoma
Childhood Osteosarcoma 		0.010 Biomarker disease BEFREE In sum, these results highlight the importance of miR-9 as an oncogene in regulating the proliferation of osteosarcoma by directly targeting GCIP and may provide new insights into the pathogenesis of osteosarcoma. 26107195 2015
CUI: C0035335
Disease: Retinoblastoma
Retinoblastoma 		0.010 AlteredExpression disease BEFREE Furthermore, in the presence of Rad, GCIP loses its ability to reduce retinoblastoma phosphorylation and inhibit cyclin D1 activity. 20460530 2010
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.010 AlteredExpression disease BEFREE Overexpression of GCIP in SW480 colon cancer cell line resulted in a significant inhibition on tumor cell colony formation, while silencing of GCIP expression by siRNA can promote cell colony formation. 17131381 2007
CUI: C0009375
Disease: Colonic Neoplasms
Colonic Neoplasms 		0.010 AlteredExpression group BEFREE In human colon tumors, both mRNA and protein expression levels of GCIP were decreased significantly compared to the normal tissues. 17131381 2007
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.010 AlteredExpression disease BEFREE Overexpression of GCIP in SW480 colon cancer cell line resulted in a significant inhibition on tumor cell colony formation, while silencing of GCIP expression by siRNA can promote cell colony formation. 17131381 2007
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.010 AlteredExpression group BEFREE In this study, we reported that the expression of GCIP was significantly downregulated in several different human tumors, including breast tumor, prostate tumor, and colon tumors. 17131381 2007
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms 		0.010 Biomarker group BEFREE Although GCIP has little inhibition on the number of hepatic tumors at later stages (40 weeks), hepatocellular tumors in GCIP transgenic mice are smaller and well-differentiated compared to the poorly differentiated tumors in wild-type mice. 16501603 2006
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation 		0.010 Biomarker phenotype BEFREE Furthermore, we demonstrate that GCIP functions as a transcriptional suppressor, regulates the expression of cyclin D1, and inhibits anchorage-independent cell growth and colony formation in HepG2 cells, suggesting a significant role of GCIP in tumor initiation and development. 16501603 2006
CUI: C1512409
Disease: Hepatocarcinogenesis
Hepatocarcinogenesis 		0.010 AlteredExpression disease BEFREE In the diethylnitrosamine (DEN)-induced mouse hepatocarcinogenesis, we demonstrated that overexpression of GCIP in mouse liver suppressed DEN-induced hepatocarcinogenesis at an early stage of tumor development. 16501603 2006
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.010 AlteredExpression disease BEFREE HHM protein was expressed in 23 of 32 AH samples (72%), 19 of 28 well-differentiated HCC samples (68%), and 9 of 18 poorly-moderately differentiated HCC samples (50%). 15887118 2005
CUI: C1857276
Disease: Trichohepatoenteric Syndrome
Trichohepatoenteric Syndrome 		0.010 GeneticVariation disease BEFREE The last 3 yr have yielded a fertile harvest of new information on the HHM clinical syndrome and on the novel peptide hormone family responsible for the syndrome. 2172279 1990
CUI: C0020437
Disease: Hypercalcemia
Hypercalcemia 		0.010 Biomarker disease BEFREE These studies demonstrate that a fragment of hHCF alone, without added or tumor-secreted cofactors or hormones, can produce hypercalcemia and other biochemical abnormalities associated with HHM. 2854715 1988